Skip to main content
. 2022 Sep 1;140(9):1009–1019. doi: 10.1182/blood.2021015114

Figure 4.

Figure 4.

OS in patients aged <65 years with stage II to IV disease. (A-B) OS in patients with ALCL, AITL, or PTCL NOS treated with or without consolidation with ASCT after chemotherapy in the first-line setting, measured in months after the 9-month landmark (LM) (A), and in patients who achieved CR in the first-line setting after induction chemotherapy with or without consolidation with ASCT (B).